about
Refining the role of PMS2 in Lynch syndrome: germline mutational analysis improved by comprehensive assessment of variantsGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskPOLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillanceNew insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposisIdentification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Integrating gene expression and epidemiological data for the discovery of genetic interactions associated with cancer risk.Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersStem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.VAV3 mediates resistance to breast cancer endocrine therapy.Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.Exploring the link between MORF4L1 and risk of breast cancer.An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-liInterplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair.Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.Functional and structural analysis of C-terminal BRCA1 missense variants.Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer casesCandidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes.Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.Identification of six new susceptibility loci for invasive epithelial ovarian cancer.Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Mammographic density and breast cancer in women from high risk families.Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscapePrediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.SEOM clinical guidelines in Hereditary Breast and ovarian cancer.MLH1 methylation screening is effective in identifying epimutation carriersCancer develops, progresses and responds to therapies through restricted perturbation of the protein-protein interaction network.Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients.
P50
Q24293661-CA4FF813-FCCA-465A-8F99-95147F618727Q27008356-8F5FD765-48CF-48C2-B4C8-DD94DD0B3CE9Q28264404-CB994F20-A260-422B-B362-868B53739943Q28307340-CCB3B564-CB72-42F3-946D-E957A5B891D6Q30252854-9A9C1E1C-3778-4D9A-8678-F75953AFC410Q30374367-B2507780-C630-4E4F-BD33-7CA0BF05C15FQ30705599-941255F9-3F5F-4B0A-AD7A-B67C8D0AC1F1Q33284158-567011F6-6302-4E7C-B8AA-ECFAF8C43C28Q33614244-40AAD370-C8ED-477E-B930-EF03D58D4BA3Q33721249-75593D9A-CA70-461E-A197-2831BF69DA59Q33761201-B7C81E3B-794D-4F4F-92D5-D7B59E5F2B7EQ33798713-606A63EF-4DDD-43BD-84F4-4818A4602A89Q33827037-AAB8645A-ED00-4B9C-9728-5E1F17FBE75DQ33850983-093A587F-346B-4CBC-AAA7-A517D060AC80Q33863235-B7A9B079-AABC-4A66-846D-ED2A7541B25BQ33901361-975822AF-C156-45BC-B072-F9F38EFDB124Q33990377-C0F3EA4F-F852-4050-9B94-B95516B8F29FQ34081324-FA6F9081-ADDC-4953-AE09-F916747A3D1AQ34188457-DDAAF847-98B7-4B0A-800C-FBE00D23E8B5Q34479613-2E547E35-CBDE-41B6-84D0-7E237A1B8D19Q34515308-D22F79EB-55BA-4000-B8B1-DE2773530D2DQ34684253-5DD37E25-463E-4174-A0BA-68D437D7293AQ34806825-EE63FB8E-CBA4-4A5D-94DF-E1863E685F97Q34917808-BB3873DC-4BCE-44AE-B814-E95902D7D4D1Q34963894-79F16659-D3BC-41AC-80C9-5A58B55182EAQ35011561-08EAD869-4961-4295-BCE2-9A8329ADD784Q35242849-8BD38A11-D4B6-46FD-8C93-23201BAC738FQ35541663-411AF7E4-E0AA-4A9F-9A53-1D39C05CA58EQ35737888-6AF11C9E-51AA-4C94-AEFF-2F8A73EA869AQ35842576-B6048232-B55D-4F88-AA01-1F25AC91E2FCQ35870067-7F6A6DC1-CA6B-4C74-AA78-0A588B6DE1DBQ35940158-D2E47284-7823-4D36-B45B-538C5A39063CQ36035692-93CBD900-9DC7-42B1-B9C7-AB0A1D72012CQ36124728-28185D28-410E-4CA1-8171-2542F1BB9924Q36239238-0B607F24-AAFA-4AE5-8EF3-FD05E78FAF47Q36356727-037DF2FB-9CC2-4408-B367-FF31003F55CCQ36400244-3690A881-9A85-4507-89CD-BB8754C81F3FQ36403949-87008A9F-9E1E-48C5-A960-DD5C98CA6936Q36424477-F03A08B4-E2BA-489C-BAF4-2A1567A0BFD8Q36464014-09F9B813-8455-408E-B719-40FE81197D96
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joan Brunet
@ast
Joan Brunet
@en
Joan Brunet
@es
Joan Brunet
@nl
Joan Brunet
@sl
type
label
Joan Brunet
@ast
Joan Brunet
@en
Joan Brunet
@es
Joan Brunet
@nl
Joan Brunet
@sl
altLabel
Joan Brunet Vidal
@en
Joan Maria Brunet Vidal
@en
prefLabel
Joan Brunet
@ast
Joan Brunet
@en
Joan Brunet
@es
Joan Brunet
@nl
Joan Brunet
@sl
P1053
C-5292-2018
P106
P21
P31
P3829
P496
0000-0003-1945-3512